The global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market size is predicted to grow from US$ 536 million in 2025 to US$ 1108 million in 2031; it is expected to grow at a CAGR of 12.9% from 2025 to 2031.
Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody is an antibody specific for CEACAM5 protein. CEACAM5, also known as fetal antigen 5 (CEA), is a membranous cell adhesion molecule that is often expressed on the surface of a variety of cancer cells, especially in cancers of the digestive tract, pancreas, and breast.
This antibody can bind to CEACAM5 protein to help detect and localize cancer cells, and can also be used in immunohistochemistry and cancer diagnosis. Due to the high expression of CEACAM5 in cancer, CEACAM5 antibodies have potential applications in tumor marker research and clinical diagnosis, helping to detect and monitor early cancer.
The 鈥淐arcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Industry Forecast鈥� looks at past sales and reviews total world Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody sales in 2024, providing a comprehensive analysis by region and market sector of projected Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody sales for 2025 through 2031. With Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody industry.
This Insight Report provides a comprehensive analysis of the global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody.
This report presents a comprehensive overview, market shares, and growth opportunities of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Monoclonal Antibody
Polyclonal Antibody
Segmentation by Application:
Flow Cytometry
ELISA
Western Blot
Immunoprecipitation
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sino Biological, Inc.
LifeSpan BioSciences, Inc
Abcam
Thermo Fisher Scientific (China) Co., Ltd.
Bio-Techne
Boster Biological Technology
Merck
RayBiotech, Inc.
Assay Genie
Creative Biolabs
MyBiosource, Inc.
OriGene Technologies, Inc.
Creative Diagnostics
Abbexa
Biorbyt
Abeomics Inc.
CUSABIO
Enzo Life Sciences, Inc.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market?
What factors are driving Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody market opportunities vary by end market size?
How does Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody break out by Type, by Application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Country/Region, 2020, 2024 & 2031
2.2 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Segment by Type
2.2.1 Monoclonal Antibody
2.2.2 Polyclonal Antibody
2.3 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type
2.3.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sale Price by Type (2020-2025)
2.4 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Segment by Application
2.4.1 Flow Cytometry
2.4.2 ELISA
2.4.3 Western Blot
2.4.4 Immunoprecipitation
2.4.5 Others
2.5 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application
2.5.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Breakdown Data by Company
3.1.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Sales by Company (2020-2025)
3.1.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Revenue by Company (2020-2025)
3.2.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Company (2020-2025)
3.2.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sale Price by Company
3.4 Key Manufacturers Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Location Distribution
3.4.2 Players Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Geographic Region
4.1 World Historic Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Sales by Country/Region (2020-2025)
4.2.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Revenue by Country/Region (2020-2025)
4.3 Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Growth
4.4 APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Growth
4.5 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Growth
4.6 Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Growth
5 Americas
5.1 Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country
5.1.1 Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2020-2025)
5.1.2 Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2020-2025)
5.2 Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2020-2025)
5.3 Americas Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region
6.1.1 APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region (2020-2025)
6.1.2 APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region (2020-2025)
6.2 APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2020-2025)
6.3 APAC Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Country
7.1.1 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2020-2025)
7.1.2 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2020-2025)
7.2 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2020-2025)
7.3 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Country
8.1.1 Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2020-2025)
8.1.2 Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2020-2025)
8.2 Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2020-2025)
8.3 Middle East & Africa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody
10.3 Manufacturing Process Analysis of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody
10.4 Industry Chain Structure of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Distributors
11.3 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Customer
12 World Forecast Review for Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Geographic Region
12.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody 麻豆原创 Size Forecast by Region
12.1.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Forecast by Region (2026-2031)
12.1.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Forecast by Type (2026-2031)
12.7 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Sino Biological, Inc.
13.1.1 Sino Biological, Inc. Company Information
13.1.2 Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.1.3 Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Sino Biological, Inc. Main Business Overview
13.1.5 Sino Biological, Inc. Latest Developments
13.2 LifeSpan BioSciences, Inc
13.2.1 LifeSpan BioSciences, Inc Company Information
13.2.2 LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.2.3 LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 LifeSpan BioSciences, Inc Main Business Overview
13.2.5 LifeSpan BioSciences, Inc Latest Developments
13.3 Abcam
13.3.1 Abcam Company Information
13.3.2 Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.3.3 Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Abcam Main Business Overview
13.3.5 Abcam Latest Developments
13.4 Thermo Fisher Scientific (China) Co., Ltd.
13.4.1 Thermo Fisher Scientific (China) Co., Ltd. Company Information
13.4.2 Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.4.3 Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Thermo Fisher Scientific (China) Co., Ltd. Main Business Overview
13.4.5 Thermo Fisher Scientific (China) Co., Ltd. Latest Developments
13.5 Bio-Techne
13.5.1 Bio-Techne Company Information
13.5.2 Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.5.3 Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Bio-Techne Main Business Overview
13.5.5 Bio-Techne Latest Developments
13.6 Boster Biological Technology
13.6.1 Boster Biological Technology Company Information
13.6.2 Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.6.3 Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Boster Biological Technology Main Business Overview
13.6.5 Boster Biological Technology Latest Developments
13.7 Merck
13.7.1 Merck Company Information
13.7.2 Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.7.3 Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Merck Main Business Overview
13.7.5 Merck Latest Developments
13.8 RayBiotech, Inc.
13.8.1 RayBiotech, Inc. Company Information
13.8.2 RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.8.3 RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 RayBiotech, Inc. Main Business Overview
13.8.5 RayBiotech, Inc. Latest Developments
13.9 Assay Genie
13.9.1 Assay Genie Company Information
13.9.2 Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.9.3 Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Assay Genie Main Business Overview
13.9.5 Assay Genie Latest Developments
13.10 Creative Biolabs
13.10.1 Creative Biolabs Company Information
13.10.2 Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.10.3 Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Creative Biolabs Main Business Overview
13.10.5 Creative Biolabs Latest Developments
13.11 MyBiosource, Inc.
13.11.1 MyBiosource, Inc. Company Information
13.11.2 MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.11.3 MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 MyBiosource, Inc. Main Business Overview
13.11.5 MyBiosource, Inc. Latest Developments
13.12 OriGene Technologies, Inc.
13.12.1 OriGene Technologies, Inc. Company Information
13.12.2 OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.12.3 OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 OriGene Technologies, Inc. Main Business Overview
13.12.5 OriGene Technologies, Inc. Latest Developments
13.13 Creative Diagnostics
13.13.1 Creative Diagnostics Company Information
13.13.2 Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.13.3 Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Creative Diagnostics Main Business Overview
13.13.5 Creative Diagnostics Latest Developments
13.14 Abbexa
13.14.1 Abbexa Company Information
13.14.2 Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.14.3 Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Abbexa Main Business Overview
13.14.5 Abbexa Latest Developments
13.15 Biorbyt
13.15.1 Biorbyt Company Information
13.15.2 Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.15.3 Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Biorbyt Main Business Overview
13.15.5 Biorbyt Latest Developments
13.16 Abeomics Inc.
13.16.1 Abeomics Inc. Company Information
13.16.2 Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.16.3 Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Abeomics Inc. Main Business Overview
13.16.5 Abeomics Inc. Latest Developments
13.17 CUSABIO
13.17.1 CUSABIO Company Information
13.17.2 CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.17.3 CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 CUSABIO Main Business Overview
13.17.5 CUSABIO Latest Developments
13.18 Enzo Life Sciences, Inc.
13.18.1 Enzo Life Sciences, Inc. Company Information
13.18.2 Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Portfolios and Specifications
13.18.3 Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Enzo Life Sciences, Inc. Main Business Overview
13.18.5 Enzo Life Sciences, Inc. Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.
